Hofseth BioCare ASA Explores Unsecured Bond Opportunities
Hofseth BioCare ASA is taking significant steps to bolster its financial strategy by exploring the issuance of CHF-denominated unsecured bonds. With an anticipated volume of up to CHF 8 million, the company is aiming to attract investors primarily in Switzerland and Liechtenstein. This move reflects Hofseth's ambition to broaden its investment base and enhance its operational capabilities.
Engagement with Investors
The company has enlisted the expertise of Novum Asset Management AG to facilitate this process effectively. Not only does Hofseth aim to attract investors from Switzerland and Liechtenstein, but it also plans to engage directly with potential investors in Norway. This dual strategy marks an important pivot in their financial outreach.
Expectations for the Bond Issuance
The proposed bonds will have a tenor of three years, which aligns with the company’s long-term strategy for sustainable growth. While specific details about the issuance and the associated terms are still to be made public, stakeholders can expect to receive more comprehensive information as this process progresses.
Contact Information
For anyone interested in learning more about this initiative, direct inquiries can be directed to Jon Olav Ødegård, the CEO of Hofseth BioCare, at +47 936 32 966 or via email at joo@hofsethbiocare.no.
About Hofseth BioCare ASA
Hofseth BioCare ASA is driven by a commitment to health, sustainability, and the effective use of natural resources. As a pioneer in the consumer and pet health sectors, Hofseth has positioned itself uniquely within the salmon industry by upcycling by-products into health-enhancing ingredients. This innovative practice not only addresses waste but also empowers their product range.
Innovative Health Products
The company produces several patented health products, including ProGo®, OmeGo®, and CalGo® / NT-II™. ProGo® is enriched with bioactive peptides that amplify iron metabolism, promoting energy and vitality. Similarly, OmeGo® offers a comprehensive salmon oil rich in essential fatty acids known to bolster immune health and respiratory conditions. Meanwhile, CalGo® contributes to bone and joint health, ideal for supporting active lifestyles and healthy aging.
Research and Collaborations
Hofseth BioCare is at the forefront of scientific research, forming key academic partnerships to validate their health product claims. These collaborations have led to breakthrough discoveries in health benefits, significantly enhancing the company's reputation in the field. Additionally, the company has launched HBC Immunology (HBCI), a spin-off that is channeling funds into new therapeutic studies, including promising approaches for prostate and ovarian cancers.
Future Directions
HBCI is exploring exciting new treatments, including a potential oral therapy aimed at reducing steroid use for asthma patients. Hofseth's commitment to innovation and health continues to thrive, making it a noteworthy player in both consumer and therapeutic health sectors.
Frequently Asked Questions
What is Hofseth BioCare ASA planning with the bonds?
Hofseth is exploring the issuance of unsecured bonds to enhance its financial capabilities and expand its investor base.
How much do they plan to raise through the bond issuance?
The company aims to raise up to CHF 8 million.
Who is assisting Hofseth in this process?
Novum Asset Management AG has been hired to facilitate the bond issuance.
What are some of Hofseth's key products?
Some of their key offerings include ProGo®, OmeGo®, and CalGo® / NT-II™, which support various health benefits.
What is the goal of HBC Immunology?
HBC Immunology focuses on developing therapeutics, including cancer treatments and alternatives for asthma management.
